Magenta down after blood cancer therapy trial shows adverse event in patients

Dianthus Therapeutics

20/12/2022 15:30

** Shares of drug developer Magenta Therapeutics Inc
 MGTA.O  fall ~42% to $0.48 
    ** Co stops dosing patients at the cohort 4 dosing level in
drug MGTA-117's early-to-mid-stage trial after dose-limiting
toxicities (DLTs) were observed in the second and third dosed
participants 
    ** The toxicity in patients involved a respiratory serious
adverse event (SAE)
    ** The drug is being studied to treat acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS)
    ** Both AML and MDS are groups of cancers associated with
the blood and bone marrow
    ** Co says it reported the clinical data of first observed
DLT to the U.S. FDA; adds information applicable to the DLT
event in the second participant is forthcoming
    ** Magenta now plans to continue enrollment and dose
additional participants at the Cohort 3 dose level
    ** Including session's fall, stock down 88.6% YTD 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))